Epidemiology and Prevention of Vaccine-Preventable Diseases
The Pink Book: Course Textbook - 13th Edition (2015)
[12 pages]
The 13th Edition Epidemiology and Prevention of Vaccine-Preventable Diseases, a.k.a. the "Pink Book," provides physicians, nurses, nurse practitioners, physician assistants, pharmacists, and others with the most comprehensive information on routinely used vaccines and the diseases they prevent.
Six appendices contain a wealth of reference materials including: vaccine minimum ages and intervals, current and discontinued vaccines, vaccine contents, foreign vaccine terms, and more.
To view online or download to print specific sections, see links below.
- Order a bound copy from the Public Health Foundation Learning Resource Center.
Table of Contents
View Online, or Download and Print the Pink Book
[4.06 MB, 24 files]Front Matter
This book was produced by the Communication and Education Branch, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, who is solely responsible for its content. It was printed and distributed by the Public Health Foundation. For additional copies, contact the Public Health Foundation at 877-252-1200 or website.
.
E-mail address for comments, questions or suggestions about the contents of this book.
Edited by:
Jennifer Hamborsky, MPH, MCHES
Andrew Kroger, MD, MPH
Charles (Skip) Wolfe
Andrew Kroger, MD, MPH
Charles (Skip) Wolfe
Suggested citation
Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015.
Disclaimer: Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Services or the U.S. Department of Health and Human Services. References to non-CDC sites on the Internet are provided as a service to readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses were current as of the date of publication.
The editors would like to thank Dr. William L. Atkinson, who summarized, standardized and compiled CDC’s vaccine-preventable disease and vaccine teaching materials to create the Pink Book.
The Pink Book: Errata, Updates & Clarifications
Epidemiology and Prevention of Vaccine-Preventable Diseases
The Pink Book: Course Textbook - 13th Edition Second Printing (2015)
Latest Entry: 9/8/2015
Clarification
Page 4 (Principles of Vaccination Chapter)
In the second paragraph under the section “Classification of Vaccines,” the last sentence is misleading. It should be replaced with, “However, two live attenuated bacterial vaccines are available in the United States (Ty21a and BCG). BCG is not used as a vaccine, but as a treatment for bladder cancer.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book.
In the second paragraph under the section “Classification of Vaccines,” the last sentence is misleading. It should be replaced with, “However, two live attenuated bacterial vaccines are available in the United States (Ty21a and BCG). BCG is not used as a vaccine, but as a treatment for bladder cancer.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book.
Erratum
Page 7 (Principles of Vaccination Chapter)
In the section titled Polysaccharide Vaccines, the last bullet on the figure under “Recombinant Vaccines” should be changed from, “Bacterial: Salmonella Typhi (Vi)” to “Bacterial: Salmonella Typhi (Ty21a).” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book.
In the section titled Polysaccharide Vaccines, the last bullet on the figure under “Recombinant Vaccines” should be changed from, “Bacterial: Salmonella Typhi (Vi)” to “Bacterial: Salmonella Typhi (Ty21a).” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book.
Erratum
Page 11 (General Recommendations on Immunization Chapter)
Under the heading Simultaneous and Nonsimultaneous Administration, the last bullet on the figure should be changed from, “Exception is yellow fever vaccine given less than 4 weeks after measles vaccine, mumps vaccine, rubella vaccine, or varicella vaccine” to “Exception is yellow fever vaccine given less than 30 days after single antigen measles vaccine, single antigen mumps vaccine, single antigen rubella vaccine, or varicella vaccine.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Under the heading Simultaneous and Nonsimultaneous Administration, the last bullet on the figure should be changed from, “Exception is yellow fever vaccine given less than 4 weeks after measles vaccine, mumps vaccine, rubella vaccine, or varicella vaccine” to “Exception is yellow fever vaccine given less than 30 days after single antigen measles vaccine, single antigen mumps vaccine, single antigen rubella vaccine, or varicella vaccine.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Clarification
Page 12 (General Recommendations on Immunization Chapter)
Under the heading Nonsimultaneous Administration of Different Vaccines, the last sentence of the first paragraph lacks precision. It should read, “So doses of mumps, varicella, zoster, LAIV, and rubella, when administered less than 30 days prior to yellow fever vaccine, can be counted.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Under the heading Nonsimultaneous Administration of Different Vaccines, the last sentence of the first paragraph lacks precision. It should read, “So doses of mumps, varicella, zoster, LAIV, and rubella, when administered less than 30 days prior to yellow fever vaccine, can be counted.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Clarification
Page 27 (General Recommendations on Immunization Chapter)
In the second paragraph under the section Tuberculin Skin Test, the word “containing” should be added to the last sentence, so it will now read, “Until such information is available, it is prudent to apply rules for spacing measles vaccine and TST to varicella-containing vaccine and LAIV.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
In the second paragraph under the section Tuberculin Skin Test, the word “containing” should be added to the last sentence, so it will now read, “Until such information is available, it is prudent to apply rules for spacing measles vaccine and TST to varicella-containing vaccine and LAIV.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Erratum
Page 51 (Vaccine Safety Chapter)
In the paragraph headed National Childhood Vaccine Injury Act (NCVIA) of 1986, the second use of the acronym “NCVIA” was erroneously printed “NVCIA.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
In the paragraph headed National Childhood Vaccine Injury Act (NCVIA) of 1986, the second use of the acronym “NCVIA” was erroneously printed “NVCIA.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Erratum
Page 101 (Vaccine Administration Chapter)
Under the heading Documentation, the bulleted lists in both the text and in the figure headed “Documentation in Permanent Medical Record” erroneously contain the bullet “Expiration date.” They should be removed. (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
Under the heading Documentation, the bulleted lists in both the text and in the figure headed “Documentation in Permanent Medical Record” erroneously contain the bullet “Expiration date.” They should be removed. (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
Erratum
Page 175 (Human Papillomavirus Chapter)
On the first figure, under the heading “Human Papillomavirus Types and Disease Association,” the text under the far-left arrow should include an additional bullet: “high-grade cervical abnormalities.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
On the first figure, under the heading “Human Papillomavirus Types and Disease Association,” the text under the far-left arrow should include an additional bullet: “high-grade cervical abnormalities.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Erratum
Page 199 (Influenza Chapter)
(1) Under the heading Contraindications and Precautions to Vaccination, “Guillain-Barré” is misspelled (as “Guillian-Barré”) twice in the text and twice in the accompanying figure. (2) In the same figure, the bullets under “Live Attenuated Influenza Vaccine Contraindications and Precautions” have been updated. (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
(1) Under the heading Contraindications and Precautions to Vaccination, “Guillain-Barré” is misspelled (as “Guillian-Barré”) twice in the text and twice in the accompanying figure. (2) In the same figure, the bullets under “Live Attenuated Influenza Vaccine Contraindications and Precautions” have been updated. (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
Updates
Page 270 (Pertussis Chapter)
(1) In the figure Tdap Recommendations, the bullet “adults 19 through 64 years of age” should read “adults 19 and older.” (2) In the same figure, the bullet beginning “adults 65 years of age and older . . .” should be deleted. (3) In the first text paragraph under the heading Tdap, the end of the last sentence should be changed from “Adacel is approved for persons 11 through 64 years of age” to “Adacel is approved for persons 10 through 64 years of age.” (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
(1) In the figure Tdap Recommendations, the bullet “adults 19 through 64 years of age” should read “adults 19 and older.” (2) In the same figure, the bullet beginning “adults 65 years of age and older . . .” should be deleted. (3) In the first text paragraph under the heading Tdap, the end of the last sentence should be changed from “Adacel is approved for persons 11 through 64 years of age” to “Adacel is approved for persons 10 through 64 years of age.” (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
Updates
Page 289 (Pneumococcal Chapter)
Under the heading Vaccine Schedule and Use, the figure heading “Pneumococcal Conjugate Vaccine High-risk Schedule – Adults 19 through 64 years old” should be changed to “Pneumococcal Conjugate Vaccine High-risk Schedule – Adults 19 and older.” (9/8/2015)This change has been made to the online html and pdf versions of the Pink Book
Under the heading Vaccine Schedule and Use, the figure heading “Pneumococcal Conjugate Vaccine High-risk Schedule – Adults 19 through 64 years old” should be changed to “Pneumococcal Conjugate Vaccine High-risk Schedule – Adults 19 and older.” (9/8/2015)This change has been made to the online html and pdf versions of the Pink Book
Updates
Page 290 (Pneumococcal Chapter)
(1) Under the figure heading “Pneumococcal Polysaccharide Vaccine Recommendations,” an additional bullet, “CFS leak” should be added. (2) In the second part of the same figure, heading “Pneumococcal Polysaccharide Vaccine Revaccination – High-risk Immunocompetent Persons,” the bullet beginning, “Revaccination recommended for immunocompetent persons 2 years of age . . .” should be changed: the phrase “2 years of age or older” should be changed to “2 through 64 years of age.” (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
(1) Under the figure heading “Pneumococcal Polysaccharide Vaccine Recommendations,” an additional bullet, “CFS leak” should be added. (2) In the second part of the same figure, heading “Pneumococcal Polysaccharide Vaccine Revaccination – High-risk Immunocompetent Persons,” the bullet beginning, “Revaccination recommended for immunocompetent persons 2 years of age . . .” should be changed: the phrase “2 years of age or older” should be changed to “2 through 64 years of age.” (9/8/2015) These changes has been made to the online html and pdf versions of the Pink Book
Clarification
Page 316 (Rotavirus Chapter)
Under the heading Vaccine Efficacy, the figure titled “Rotavirus Vaccine Efficacy” is confusing. It should read:
Under the heading Vaccine Efficacy, the figure titled “Rotavirus Vaccine Efficacy” is confusing. It should read:
Rotavirus Vaccine Efficacy
- Any rotavirus gastroenteritis: 74%-87%
- Severe gastroenteritis: 85%-98%
Both vaccines significantly reduced physician visits for diarrhea, and reduced rotavirus-related hospitalization.
(9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Clarification
Page 349 (Tetanus Chapter)
Under the heading Contraindications and Precautions to Vaccination, the following sentence should be added to the end of the first paragraph: “If moderate to severe acute illness accompanies a wound that is neither clean nor minor, the risk of withholding tetanus-toxoid vaccine outweighs the risk of administering tetanus-toxoid vaccine, so the vaccine should be given as part of wound management.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
Under the heading Contraindications and Precautions to Vaccination, the following sentence should be added to the end of the first paragraph: “If moderate to severe acute illness accompanies a wound that is neither clean nor minor, the risk of withholding tetanus-toxoid vaccine outweighs the risk of administering tetanus-toxoid vaccine, so the vaccine should be given as part of wound management.” (9/8/2015) This change has been made to the online html and pdf versions of the Pink Book
.png)
No hay comentarios:
Publicar un comentario